Advertisement

Advertisement

sarcoma

Martin McCabe, PhD, on Ewing Sarcoma: Assessment of Topotecan, Cyclophosphamide, and High-Dose Ifosfamide

Martin McCabe, PhD, of the University of Manchester, discusses a phase III assessment of chemotherapy for patients with recurrent and primary refractory Ewing sarcoma. The trial, called rEECur, is the first study to provide comparative toxicity and survival data for the four most commonly used chemotherapy regimens in this disease. The analysis showed that high-dose ifosfamide is more effective in prolonging survival than topotecan plus cyclophosphamide (Abstract LBA2).

Sarcoma
Immunotherapy

Neoadjuvant Immunotherapy May Improve Survival for Patients With Soft-Tissue Sarcoma

In a phase II clinical trial, immune checkpoint blockade before surgery was associated with favorable responses and outcomes in undifferentiated pleomorphic sarcoma (UPS) and recurrent dedifferentiated liposarcoma (DDLPS), Keung et al reported at the 2022 ASCO Annual Meeting (Abstract LBA11501)....

Sarcoma

Study Finds High-Dose Ifosfamide Superior to Other Standard-of-Care Treatments in Recurrent and Primary Refractory Ewing Sarcomas

Use of high-dose ifosfamide was found to be superior for treating recurrent and primary refractory Ewing sarcomas compared with three other standard-of-care treatments used for the disease, according to research presented by McCabe et al during the Plenary Session at the 2022 ASCO Annual Meeting...

Sarcoma

Addition of High-Dose Treosulfan and Melphalan to Consolidation in High-Risk Ewing Sarcoma

In a phase III trial (Ewing 2008R3) reported in the Journal of Clinical Oncology, Koch et al found that the addition of treosulfan and melphalan high-dose chemotherapy (TreoMel-HDT) followed by reinfusion of autologous hematopoietic stem cells to consolidation did not improve event-free survival vs ...

Sarcoma

Selinexor in Previously Treated Advanced Dedifferentiated Liposarcoma

In the phase II/III SEAL trial reported in the the Journal of Clinical Oncology, Gounder et al found that selinexor significantly improved progression-free survival and time to subsequent treatment in previously treated advanced dedifferentiated liposarcoma, with the greatest benefit observed in...

Sarcoma

Addition of Carotuximab to Pazopanib in Advanced Angiosarcoma

In the phase III TAPPAS trial reported in JAMA Oncology, Jones et al found that the addition of carotuximab to pazopanib did not improve progression-free survival in patients with advanced angiosarcoma. Carotuximab is an IgG1 antibody that binds endoglin, which is highly expressed on proliferating...

Immunotherapy
Sarcoma

PD-1 Inhibition in Patients With Classic or Endemic Kaposi Sarcoma

In a French phase II study reported in The Lancet Oncology, Delyon et al found that pembrolizumab produced a high response rate in patients with classic or endemic Kaposi sarcoma with progressive cutaneous extension requiring systemic treatment. As stated by the investigators, “Although the...

Sarcoma

Researchers Identify Trends in Treatment for Retroperitoneal Soft-Tissue Sarcoma

Researchers have published an analysis of strategies for treating retroperitoneal soft-tissue sarcoma, which has historically been understudied due to its rarity. The researchers say the trends they identified—particularly the convergence of certain treatments across centers—will help guide the way ...

Sarcoma
Issues in Oncology

The Virtues of Ruth: Gratitude, Advocacy, and Service

I still remember having to sit down with her three siblings on that afternoon. It was drizzling, cloudy, and cool—Mother Nature in agreement with the heaviness of what had just taken place. I held them tight. I knew the words I would utter next would change their lives forever. I paused for 10...

Solid Tumors
Sarcoma

Antibiotics After Endoprosthetic Reconstruction for Lower-Extremity Bone Tumors: Comparison of Two Intravenous Regimens

In a study reported in JAMA Oncology, researchers in the Prophylactic Antibiotic Regimens in Tumor Surgery Investigators group found that 5 days vs 1 day of postoperative intravenous antibiotic prophylaxis did not reduce the incidence of surgical site infection and was associated with more...

Sarcoma

Sirolimus Protein-Bound Particles for Malignant Perivascular Epithelioid Cell Tumor

On November 22, 2021, sirolimus protein-bound particles for injectable suspension (albumin-bound) was approved for treatment of adults with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor.1 Supporting Efficacy Data Approval was supported by findings in the...

sarcoma
immunotherapy

Emily Z. Keung, MD, on Interactions of Sarcoma, Immune Infiltrates, and Checkpoint Blockade

Emily Z. Keung, MD, of The University of Texas MD Anderson Cancer Center, discusses the complex interactions of immune infiltrates and neoadjuvant immune checkpoint blockade (ICB) in patients with resectable soft-tissue sarcoma. These interactions may hold the key to understanding pathologic response to ICB and ICB resistance (Abstract 379).

Sarcoma

From Cancer Survivor to Citizen Astronaut

When I was diagnosed with osteosarcoma of my left femur nearly 20 years ago, I remember telling my parents that I didn’t want to die. The diagnosis was terrifying because all the people I knew who had cancer had passed away, and I thought this cancer would kill me, too. That evening, my dad went...

Sarcoma

Addition of Vincristine, Topotecan, and Cyclophosphamide to Five-Drug Interval-Compressed Chemotherapy for Ewing Sarcoma

As reported in the Journal of Clinical Oncology by Leavey et al, the phase III Children’s Oncology Group AEWS1031 trial showed no improvement in event-free or overall survival with the addition of vincristine, topotecan, and cyclophosphamide (VTC) to standard five-drug interval-compressed...

Sarcoma

Risk-Based Treatment of Pediatric and Young Adult Synovial Sarcoma

In a report from the Children’s Oncology Group ARST0332 study published in the Journal of Clinical Oncology, Venkatamani et al found that risk-based treatment of pediatric and young adult patients with synovial sarcoma produced favorable outcomes in those with nonmetastatic disease. Outcomes in...

Sarcoma

Activity of Nab-sirolimus in Malignant Perivascular Epithelioid Cell Tumors

In the phase II AMPECT trial reported in the Journal of Clinical Oncology, Wagner et al found that the mTOR inhibitor nab-sirolimus produced a substantial rate of durable responses and a high disease control rate in patients with malignant perivascular epithelioid cell tumors. As stated by the...

Sarcoma

Combination of Lenvatinib and Etoposide/Ifosfamide for Relapsed or Refractory Osteosarcoma

In the phase I/II ITCC-050 trial reported in The Lancet Oncology, Gaspar et al found that the combination of lenvatinib with etoposide/ifosfamide showed antitumor activity, including good progression-free survival outcomes, in patients with relapsed or refractory osteosarcoma. Study Details...

Sarcoma
Immunotherapy

Small Study Evaluates Combination Ipilimumab/Nivolumab in Patients With Angiosarcoma

In a small study of 16 patients with angiosarcoma published by Michael Wagner, MD, and colleagues in the Journal for ImmunoTherapy of Cancer, 4 patients experienced a partial or complete response to treatment with a combination of the immunotherapies ipilimumab and nivolumab, and another 2 patients ...

Gastrointestinal Cancer
Sarcoma

VOYAGER Trial: Avapritinib vs Regorafenib in Molecularly Unselected Previously Treated Advanced GIST

As reported in the Journal of Clinical Oncology by Yoon-Koo Kang, MD, and colleagues, the phase III VOYAGER trial showed no improvement in progression-free survival with avapritinib vs regorafenib as third- or later-line treatment of patients with molecularly unselected, locally advanced,...

Sarcoma

Vincristine/Irinotecan With or Without Temozolomide for Relapsed or Refractory Rhabdomyosarcoma

In a European phase II trial (VIT-0910) reported in the Journal of Clinical Oncology, Defachelles et al found that the combination of vincristine/irinotecan with vs without temozolomide produced better outcomes—albeit with increased toxicity—in children and adults with relapsed or refractory...

Sarcoma

ASTRO Issues New Clinical Guideline on Radiation Therapy for Adult Patients With Soft-Tissue Sarcoma

A new clinical guideline from the American Society for Radiation Oncology (ASTRO) published by Kilian E. Salerno, MD, and colleagues in Practical Radiation Oncology provides guidance on the use of radiation therapy to treat adult patients with soft-tissue sarcomas. Recommendations outline optimal...

Sarcoma
Immunotherapy

Addition of Prime-Boost Vaccination Regimen to Atezolizumab in Soft-Tissue Sarcomas Expressing NY-ESO-1

In a phase II trial reported in the Journal of Clinical Oncology, Sant P. Chawla, MD, and colleagues found that the addition of the heterologous prime-boost vaccination regimen CMB305 to atezolizumab did not improve survival outcomes in patients with soft-tissue sarcomas expressing the...

Sarcoma

Predicting Survival in Patients With Extremity and Trunk Sarcomas in the United States

An examination of the online nomogram Sarculator demonstrated it is as effective at predicting overall survival of certain patients with sarcoma in the United States as it is in Europe, according to research presented by Voss et al at the Society of Surgical Oncology 2021 International Conference...

Immunotherapy
Gastroesophageal Cancer
Gastrointestinal Cancer
Colorectal Cancer
Bladder Cancer
Skin Cancer
Sarcoma
Hepatobiliary Cancer

FDA Pipeline: Priority Reviews for Immunotherapies in Gastric Cancers, Anal Cancer

The U.S. Food and Drug Administration (FDA) recently granted Priority Review to nivolumab as either adjuvant or first-line therapy in several types of gastric cancers, as well as to a novel PD-1 inhibitor for locally advanced or metastatic squamous cell carcinoma of the anal canal. The FDA also...

Sarcoma

Addition of Gemcitabine to Pazopanib for Refractory Soft-Tissue Sarcoma

In the German phase II PAPGEMO trial reported in JAMA Oncology, Hans-Joachim Schmoll, MD, PhD, and colleagues found that the combination of pazopanib and gemcitabine improved 12-week progression-free survival vs pazopanib alone in patients with anthracycline- or ifosfamide-refractory soft-tissue...

Immunotherapy
Solid Tumors
Sarcoma

Progress Report on Checkpoint Inhibitors in Rare Tumors

Immune checkpoint inhibitors may prove to be effective in treating patients with two rare cancer types—leptomeningeal metastases and angiosarcoma, according to early-phase clinical trials reported at the 2020 Annual Meeting of the Society for Immunotherapy of Cancer (SITC), which was held virtually ...

Sarcoma

Complexity of Designing Clinical Trials for Sarcoma: Shifting Focus to Constellation of Subtypes

Sarcoma has bedeviled researchers for many years because of its heterogeneity. Sarcoma encompasses more than 100 different subtypes, which makes it difficult to design studies to identify effective therapies. As researchers dig deeper into the constellation of subtypes of sarcoma, some therapies...

Sarcoma

Preoperative Radiotherapy Dose Reduction in Patients With Myxoid Liposarcoma

In the phase II DOREMY trial reported in JAMA Oncology, Lansu et al found that a reduction in preoperative radiotherapy dose was effective and associated with reduced morbidity in patients with myxoid liposarcoma. A stated by the investigators, “Currently, preoperative radiotherapy for all...

Sarcoma

Tazemetostat in Patients With Advanced Epithelioid Sarcoma and Loss of INI1/SMARCB1

As reported in The Lancet Oncology by Mrinal Gounder, MD, and colleagues, findings in a cohort of a phase II basket trial showed that the oral EZH2 inhibitor tazemetostat produced durable responses in some patients with advanced epithelioid sarcoma with loss of INI1 or SMARCB1 (the gene encoding...

sarcoma

Matti S. Aapro, MD, on Curing Sarcomas: An Expert Review

Matti S. Aapro, MD, of the Genolier Cancer Center, reviews the state of the science in sarcoma treatment: specialized surgery, disease diversity, emerging therapies, and the diagnostic approach to soft-tissue disease.

Sarcoma
Immunotherapy

Does Pembrolizumab Monotherapy Demonstrate Benefit in Rare Sarcomas?

Pembrolizumab monotherapy induced responses in patients with rare sarcomas that varied by histotype, according to findings presented by Jean-Yves Blay, MD, at the ESMO Virtual Congress 2020 (Abstract 1619O). Methods Dr. Blay presented first results from a cohort of patients with rare sarcomas in...

Sarcoma

Surgery With or Without Preoperative Radiotherapy for Primary Retroperitoneal Sarcoma

As reported in The Lancet Oncology by Bonvalot et al, the phase III EORTC-62092 (STRASS) trial showed that the addition of preoperative radiotherapy to surgery did not improve abdominal recurrence–free survival in patients with primary retroperitoneal sarcoma. Study Details In the open-label trial, ...

Sarcoma

First-Line Pazopanib vs Doxorubicin in Patients Aged 60 or Older With Metastatic Soft-Tissue Sarcoma

In a German Intergroup phase II study reported in the Journal of Clinical Oncology, Grünwald et al found that progression-free survival with first-line pazopanib was noninferior to doxorubicin in patients aged 60 years or older with inoperable metastatic soft-tissue sarcoma. Pazopanib was also...

Sarcoma

Comparing Pazopanib to Doxorubicin in Patients Aged 60 and Older With Soft-Tissue Sarcoma

Doxorubicin is a standard of care in patients with advanced inoperable soft-tissue sarcoma. In the EPAZ study, German researchers tested whether pazopanib showed comparable efficacy to doxorubicin in the first-line treatment of elderly patients with soft-tissue sarcoma. Grünwald et al reported in...

Sarcoma

Addition of Pazopanib to Preoperative Chemoradiotherapy in Children and Adults With Soft-Tissue Sarcoma

In an interim analysis of a joint Children’s Oncology Group and NRG Oncology phase II trial (ARST1321) reported in The Lancet Oncology, Aaron R. Weiss, DO, and colleagues found that the addition of pazopanib to preoperative chemoradiotherapy significantly increased the rate of pathologic...

sarcoma

Patricia Pautier, MD, on Leiomyosarcoma: Doxorubicin and Trabectedin for First-Line Treatment

Patricia Pautier, MD, of Institut Gustave Roussy, discusses final results of the phase II LMS-02 study, which showed the combination of doxorubicin and trabectedin to be an effective first-line therapy for patients with leiomyosarcoma, with an acceptable safety profile (Abstract 11506).

Sarcoma

Standard vs Histology-Tailored Neoadjuvant Chemotherapy for High-Risk Soft-Tissue Sarcoma

As reported in the Journal of Clinical Oncology by Alessandro Gronchi, MD, and colleagues, final results of a phase III trial conducted by the Italian, French, and Polish Sarcoma Groups showed no disease-free or overall survival benefit with use of histology-tailored vs standard...

Sarcoma

FDA Approves Pomalidomide for Kaposi Sarcoma

On May 14, 2020, the U.S. Food and Drug Administration (FDA) expanded the indication of pomalidomide (Pomalyst) to include treating adult patients with acquired immunodeficiency syndrome (AIDS)-related Kaposi sarcoma after failure of highly active antiretroviral therapy and those with Kaposi...

Sarcoma
Skin Cancer
CNS Cancers

Early Signs of Activity With Immunotherapies in Low-Incidence Cancers

Immunotherapy is showing promise for patients with rare cancers, offering new treatment opportunities and clinical trials to those with previously limited options. At the 2020 ASCO-SITC Clinical Immuno-Oncology Symposium, presenters discussed the use of immunotherapy in three low-incidence cancers: ...

Sarcoma

Outcomes in Patients With Retroperitoneal Soft-Tissue Sarcoma by Hospital Type

In a study reported in JCO Oncology Practice, Villano et al found that increased hospital surgical volume was associated with overall improved survival in patients undergoing surgery for retroperitoneal soft-tissue sarcoma. However, increased volume was associated with poorer survival in patients...

Sarcoma

Is Ivosidenib Active in Patients With Advanced IDH1-Mutated Chondrosarcoma?

In a phase I study reported in the Journal of Clinical Oncology, William D. Tap, MD, and colleagues found that the selective mutant-IDH1 inhibitor ivosidenib produced no objective responses but resulted in durable disease control in a cohort of patients with advanced chondrosarcoma. As noted by...

Sarcoma

Tazemetostat for Advanced Epithelioid Sarcoma

On January 23, 2020, tazemetostat was granted accelerated approval for the treatment of adults and pediatric patients aged 16 and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.1,2 Supporting Efficacy Data Approval was based on the finding of...

Sarcoma

Cabozantinib for Advanced Ewing Sarcoma or Osteosarcoma

In the French phase II CABONE trial reported in The Lancet Oncology, Italiano et al found that the MET and VEGFR2 inhibitor cabozantinib was active in patients with advanced Ewing sarcoma or osteosarcoma. Study Details In the multicenter trial, 81 evaluable patients aged ≥ 12 years with progressive ...

Sarcoma

Immunogenomic Profiling of Osteosarcoma

Comprehensive profiling of tumor samples taken from patients with osteosarcoma showed that multiple factors contribute to the traditionally poor responses observed with immune checkpoint inhibitor treatment in patients with this malignancy, according to new research published by Wu et al in Nature...

Sarcoma
Immunotherapy

Immunotherapy Combination in Previously Treated Advanced Sarcoma

In a single-institution phase II study reported in JAMA Oncology, Kelly et al found that the combination of talimogene laherparepvec (T-VEC) and pembrolizumab produced durable responses in patients with previously treated advanced sarcoma. As noted by the investigators, T-VEC has been found to...

Sarcoma

FDA Approves Tazemetostat for Epithelioid Sarcoma

On January 23, the U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat (Tazverik) for adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. “Epithelioid sarcoma accounts...

Sarcoma

Pathologic Fracture and Prognosis in Adult and Pediatric Patients With High-Grade Osteosarcoma

In a study reported in the Journal of Clinical Oncology, Kelley et al found that pathologic fracture was associated with poorer overall survival among adult—but not pediatric—patients with primary central high-grade osteosarcoma of the extremities. Study Details The study involved retrospective...

Immunotherapy
Skin Cancer
Sarcoma
Kidney Cancer

Three Studies Examine Relationship Between B-Cell Enrichment and Response to Immunotherapy

The likelihood of a patient responding to immune checkpoint blockade may depend on B cells in the tumor, located within specialized immune-cell clusters known as tertiary lymphoid structures, according to three studies all recently published in Nature. The studies showed that enrichment of B cells...

multiple myeloma
sarcoma
immunotherapy

Edward A. Stadtmauer, MD, on Advanced Multiple Myeloma and Sarcoma: First-in-Human Assessment of CRISPR-Edited T Cells

Edward A. Stadtmauer, MD, of the University of Pennsylvania Abramson Cancer Center, discusses phase I results of immune cells, modified with CRISPR/Cas9 technology, and infused in three patients (two with multiple myeloma and one with sarcoma). Researchers observed the cells expand and bind to their tumor targets with no serious side effects (Abstract 49).

Sarcoma

Maintenance Chemotherapy Improves Survival in High-Risk Rhabdomyosarcoma

In the phase III RMS 2005 trial reported by Gianni Bisogno, MD, and colleagues in The Lancet Oncology, maintenance vinorelbine and low-dose continuous cyclophosphamide was associated with nonsignificant improvement in disease-free survival and significantly improved overall survival vs no further...

Advertisement

Advertisement

Advertisement